环氧化酶-2及血管内皮生长因子在宫颈癌及其癌前病变中的表达

目的探讨环氧化酶-2（cyclooxygenenase-2,COX-2）的表达与宫颈癌发生的关系以及COX-2与血管内皮生长因子vascular endothelial growth factor,VEGF）表达的关系。方法采用免疫组化（S-P）法检测20例正常宫颈、26例低度宫颈上皮内瘤变（cervical intraepithelial neoplasia,CIN;CIN Ⅰ）、28例高度CIN（CIN Ⅱ／Ⅲ）、25例宫颈癌组织中COX-2、血管内皮生长因子vascular endothelial growth faclor,VEGF）的表达,并分析COX-2与VEGF及高危HPV感染的关系。结果在正常宫颈、低度CIN、高度CIN、宫颈癌中COX-2的表达率分别为0、23．08％、57．14％、84％,VEGF的表达率分别为5％、30．77％、60．71％、88％,两者均随着病变的加重表达率明显增加,差异均有统计学意义（P〈0．001）。COX-2表达与VEGF呈显著正相关（P=0．001）。人乳头瘤病毒（HPV）在低度CIN、高度CIN及宫颈癌的感染率分别为30．77％、71．43％、100％,在宫颈癌及其癌前病变中,COX-2与高危HPV感染率呈正相关（P=0．021）。结论COX-2与宫颈癌的发生、发展有关,并可能与肿瘤的血管生成有密切的关系。COX-2可能成为宫颈癌早期防治的靶点。     

环氧合酶-2在子痫前期患者胎盘组织中的表达

目的研究环氧合酶-2(COX-2)在子痫前期患者胎盘组织中的表达,探讨其在子痫前期发病机制中的作用。方法采用免疫组化SP法检测50例子痫前期患者(轻度30例,重度20例)胎盘组织中COX-2的表达,20例正常孕妇为对照组。应用逆转录多聚酶链反应(RT-PCR)检测30例子痫前期患者及12例正常孕妇的胎盘组织中COX-2mRNA的表达。结果(1)COX-2主要表达于胎盘血管内皮细胞。子痫前期患者COX-2蛋白的表达均明显增高,且随病情严重程度的增加而升高。子痫前期组COX-2蛋白的阳性表达率为63.1%、显著高于对照组(COX-2阳性表达率为23%)(P<0.01)。(2)子痫前期组COX-2mRNA表达水平为0.61±0.25,对照组为0.66±0.71,两组比较,差异无显著性(t=-0.93,P>0.05)。结论COX-2参与了子痫前期胎盘螺旋小动脉动脉粥样硬化。     

脑胶质瘤表皮生长因子受体表达及其意义

脑胶质瘤表皮生长因子受体表达及其意义袁志忠叶挺军陈泳莲近十年来，国外的研究已证实，胶质瘤常有表皮生长因子受体（ｅｐｉｄｅｒｍａｌｇｒｏｗｔｈｆａｃｔｏｒｒｅｃｅｐｔｏｒ，ＥＧＦＲ）基因扩增、重排及蛋白产物的过度表达和结构异常，且与肿瘤的发生和发展有关...     

表皮生长因子、转化生长因子-α及其受体在人垂体腺瘤组织中的表达

目的探讨表皮生长因子 (EGF)、转化生长因子 α(TGF α)和表皮生长因子受体 (EGFR)在垂体腺瘤发生、发展过程中的作用。方法应用放射性原位分子杂交法 ,观察上述3种分子的表达。结果在检测的22例垂体腺瘤组织中 ,分别有17例 (77 % )、12例(55 %)和20例(91 %)显示有EGF ,TGF α和EGFRmRNA的过度表达 ,它们在正常垂体组织中的阳性率分别为42 % ,25 %和42 %。不同的垂体腺瘤组织中3种mRNA的表达强度有差异。结论垂体腺瘤中存在着EGF/EGFR或/和TGF α/EGFR自分泌系统 ,该系统在垂体腺瘤的分化及增殖过程中可能起着重要的作用。     

环氧合酶-2在酒精性肝病中表达增强

目的探讨环氧合酶2(COX-2)在酒精性肝病(ALD)发病机制中的作用。方法用酒精灌胃建立大鼠酒精性肝病模型,分别于4、8、12和16周取肝组织,用生化比色法检测肝匀浆6-酮-前列腺素F1α(6-K-PGF1α)、血栓素B2(TXB2)、甘油三酯(TG)、氧自由基(ORF)、抗超氧阴离子(ASOA)、超氧化物歧化酶(SOD)及丙二醛(MDA)含量;用HE、苏丹Ⅳ和天狼猩红染色观察肝组织病理形态;RT-PCR法观察肝组织COX-2 mRNA表达。结果4、8、12和16周的大鼠肝组织COX-2 mRNA相对表达量分别为正常对照组的1.29、1.70、1.92、3.38倍,除4周外P<0.01;COX-2蛋白表达逐渐增强;肝组织COX-2 mRNA相对表达量与肝匀浆OFR、MDA、TG、和TXB2呈正相关(P<0.01);与ASOA、SOD、6-K-PGF1α呈负相关(P<0.01)。结论COX-2与酒精所致大鼠肝脏病变密切相关,是ALD发病过程中重要因素之一。结论COX-2与氧化应激密切相关,二者在ALD发病中发挥重要作用。     

表皮生长因子及其受体在食管癌中的表达

目的 研究表皮生长因子（ＥＧＦ）及其受体（ＥＧＦＲ）在食管鳞状细胞癌中的表达。方法 用免疫组织化学ＡＢＣ法分析并研究染色结果与病理改变之间的关系。ＥＧＦ染色,以正常人颌下腺作为阳性对照。ＥＧＦＲ以正常人胎盘组织为阳性对照。ＥＧＦ和ＥＧＦＲ染色一抗的浓度分别为１：２００,１：１００,４℃孵育４８ｈ。结果 ＥＧＦ强阳性１８例,弱阳性１６例,ＥＧＦＲ强阳性１８例,弱阳性１６例。ＥＧＦ和ＥＧＦＲ的表达分为     

表皮生长因子受体在喉癌中的表达及其临床意义

表皮生长因子受体在喉癌中的表达及其临床意义牛晨阳王国宪刘俊英杨木兰一、材料和方法采用解放军第四五七医院病理科１９８８～１９９３年间３２例喉鳞癌常规石蜡包埋标本。按Ｂｒｏｄｅｒｓ病理分级：Ⅰ级９例、Ⅱ级１１例、Ⅲ级１０例、Ⅳ级２例；临床分期（ＵＩＣＣＴ...     

晚期胃癌患者癌组织人表皮生长因子受体-2蛋白表达及与生存时间的关系

目的:观察人表皮生长因子受体-2(HER-2/neu)蛋白表达在晚期胃癌患者不同情况下的分布及与患者生存时间的关系。方法:收集60例胃癌患者的临床资料和HER-2/neu免疫组化检测结果,分析HER-2/neu蛋白表达在不同性别、年龄、病理分型、癌变部位及转移器官数量胃癌患者中的阳性率,并比较HER-2/neu阳性、阴性患者的生存时间。结果:60例胃癌患者中HER-2/neu蛋白阳性者10例,阳性率为16.67%;不同性别及≤60岁和60岁患者间HER-2/neu阳性表达率差异无统计学意义(P0.05)。不同癌变部位、不同病理分型和不同转移器官数量胃癌患者间HER-2/neu阳性表达率差异均有统计学意义(P0.05)。10例HER-2/neu蛋白阳性者中位生存期为2.89个月,而HER-2/neu蛋白阴性者中位生存期为11.9个月,生存时间12个月者多于其总数的1/2(32例),生存时间24个月者6例。HER-2/neu阴性胃癌患者预后显著好于HER-2/neu阳性胃癌患者。结论:胃癌患者HER-2/neu蛋白表达阳性,提示预后不佳。     

表皮生长因子受体与雌,孕激素受体在乳腺癌组织中的表达及相互关系

本文应用碘标记的表皮生长因子，用分步离心提取部细胞膜蛋白，以标准的ＥＧＦ作竞争剂，采取放射标记结合法测定了４０例乳腺癌组织中的表皮生长因子受体水平，同时采用葡聚糖活性碳分析法测定了乳腺癌组织中的雌激素受体，孕激素受体以探讨ＥＧＦＲ表达与ＥＲ，ＰＲ在乳腺癌组织中的生物学行为及相互关系。     

血管内皮生长因子及其受体flt-1在宫颈癌中的表达和意义

我们拟通过观察血管内皮生长因子 (ＶＥＧＦ)与其受体ｆｌｔ 1在宫颈癌中的表达 ,探讨其与宫颈癌的生长、浸润、转移的关系 ,及其在间质血管生成中的作用和相互关系。一、材料和方法收集 1998年 9月至 2 0 0 0年 8月白求恩医科大学第一、二临床学院及吉林省肿瘤医院手术切除宫颈癌标本 72例 ,慢性宫颈炎 6例 ,患者术前均未经任何抗癌治疗 ,确诊为宫颈癌 ,其中腺癌 7例 ,鳞癌 6 5例。患者平均年龄 45岁 ,最大为 5 6岁 ,最小为 2 7岁。组织经常规石蜡包埋后做 4μｍ连续切片 ,行ＨＥ和免疫组织化学链霉素抗生物素 过氧化酶 (ＳＰ)法染色。一…     

The epidermal growth factor receptor in human pancreatic cancer.

The epidermal growth factor receptor (EGFR) and its ligands are thought to be important in the control of proliferation of many epithelial systems, including the exocrine pancreas. Abnormalities in expression of two of the known ligands of the EGFR, transforming growth factor alpha and epidermal growth factor, occur frequently in ductal adenocarcinoma of the human pancreas. We have examined an archival series of cases of pancreatic pathology for expression of the EGFR using the anti-EGFR antiserum 12E and found that there is almost ubiquitous overexpression of EGFR in pancreatic cancer and in chronic pancreatitis. Southern blot analysis showed no evidence of amplification or rearrangement of the EGFR gene. We conclude that an autocrine loop involving the EGFR system may be involved in the genesis of both neoplasia and reactive hyperplasia of pancreatic ductal epithelium.     

Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications

Epidermal growth factor receptor (EGFR) signaling and components of the fibrinolytic system, including urokinase-type plasminogen activator (uPA) and thrombomodulin (TM), have been implicated in tumor progression. In the present study, we employed cBioPortal platform (http://www.cbioportal.org/), cancer cell lines, and an in vivo model of immunocompromised mice to evaluate a possible cooperation between EGFR signaling, uPA, and TM expression/function in the context of cervical cancer. cBioPortal analysis revealed that EGFR, uPA, and TM are positively correlated in tumor samples of cervical cancer patients, showing a negative prognostic impact. Aggressive human cervical cancer cells (CASKI) presented higher gene expression levels of EGFR, uPA, and TM compared to its less aggressive counterpart (C-33A cells). EGFR induces uPA expression in CASKI cells through both PI3K-Akt and MEK1/2-ERK1/2 downstream effectors, whereas TM expression induced by EGFR was dependent on PI3K/Akt signaling alone. uPA induced cell-morphology modifications and cell migration in an EGFR-dependent and -independent manner, respectively. Finally, treatment with cetuximab reduced in vivo CASKI xenografted-tumor growth in nude mice, and decreased intratumoral uPA expression, while TM expression was unaltered. In conclusion, we showed that EGFR signaling regulated expression of the fibrinolytic system component uPA in both in vitro and in vivo settings, while uPA also participated in cell-morphology modifications and migration in a human cervical cancer model.     

158例肺癌表皮生长因子受体检测及其意义探讨

目的；探讨表皮生长因子受体（ＥＧＦＲ）在肺癌中的表达特征及其临床病理意义。方法：应用ＡＢＣ免疫组织化学法对１５８例肺癌组织进行ＥＧＦＲ检测。结果：非小细胞肺 ＥＧＦＲ阳性率为８０．６％，而小细胞肺癌的ＥＧＦＲ均为阴性，并发现非小细胞肺癌ＥＧＦＲ表达与癌的组织学类型、分化程度、生物行为、肿块大小和临床分期均无相关性。结论：检测肺癌的ＥＧＦＲ有助于鉴别小细胞肺癌和非小细胞肺癌，并认为关于ＥＧＦＲ可能是     

干扰表皮生长因子受体磷酸化过程对乳腺癌的抑制效应

目的 探讨干扰表皮生长因子受体(EGFR)的磷酸化过程对裸鼠乳腺癌移植瘤生长的影响及其作用机制.方法 建立裸鼠乳腺癌移植瘤模型,成型后随机分为Ad5-hSulf1组、Ad5-EGFP组和对照组,干预治疗后,测量计算移植瘤生长率,采用免疫组化法检测各组裸鼠移植瘤hSulf-1、EGFR和p-EGFR阳性表达,采用Western blot法检测各组裸鼠移植瘤hSulf-1、EGFR和p-EGFR蛋白表达.结果 Ad5-hSulf1组裸鼠注射治疗后第14天、21天和28天的肿瘤生长率[(165.9±23.8)％,(172.6±25.9)％,(377.3±30.5)％]明显小于同期的对照组,差异均具有统计学意义(t=12.153,21.247,14.587;P =0.000).Ad5-hSulf1组裸鼠移植瘤p-EGFR阳性表达率(46.7％)和蛋白表达[(52.7±7.4)％]明显低于Ad5-EGFR组和对照组,差异均有统计学意义(x2=8.146,t=7.384,7.587;P =0.004、0.000、0.000).结论 使用hSulf1基因抑制乳腺癌细胞的EGFR磷酸化过程,可产生明显的肿瘤抑制效应,对寻求肿瘤基因治疗的一个很有潜力的靶点具有很好的借鉴参考意义.     

表皮生长因子受体和P53与食管鳞状细胞癌放疗敏感性的关系

目的 分析食管鳞状细胞癌患者标本中表皮生长因子受体(EGFR)和P53表达水平与其临床病理特征的相关性,探讨术前放疗对EGFR和P53表达的影响,为临床食管鳞状细胞癌手术联合放疗的治疗策略提供理论依据.方法 采用免疫组织化学方法检测食管鳞状细胞癌患者标本中EGFR、P53蛋白的表达水平,分析其表达与食管鳞状细胞癌临床病理参数的关系,对比术前放疗对患者癌组织中EGFR和P53表达水平的影响.结果 与正常食管黏膜上皮组织相比,食管鳞状细胞癌组织中EGFR和P53的表达水平均显著升高;食管鳞状细胞癌组织中EGFR和P53的表达均与其组织学分级、浸润程度、有无区域淋巴结转移呈正相关;术前放射治疗可显著降低食管鳞状细胞癌组织中EGFR和P53的表达水平.结论 在食管鳞状细胞癌中,EGFR和P53的表达水平与其临床病理特征有密切关系,且呈正相关,检测两种蛋白的表达水平对食管鳞状细胞癌的恶性程度及预后判断具有重要的临床意义.     

About a case of GIST occurring during pregnancy with immunohistochemical expression of epidermal growth factor receptor and progesterone receptor

The coexistence of gastrointestinal stromal tumors (GISTs) and pregnancy is very rare. We are the first to add to the literature a case report of GIST occurring during pregnancy with immunohistochemical staining for epidermal growth factor receptor (EGFR) and progesterone receptor (PgR). A role of PgR and EGFR in tumor growth should not be excluded, and these findings indicate that the expression of these receptors could provide pertinent biological information required to determine adequate therapeutic regimens. In conclusion, considering that GIST occurring during pregnancy is a rare event, with frequent delay in diagnosis, it is important to consider this diagnosis for early recognition, correct diagnosis, and a better outcome.     

Immunohistochemical detection of the epidermal growth factor receptor in paraffin-embedded human tissues.

Expression of the epidermal growth factor (EGF) receptor was evaluated by immunohistochemical staining of formalin-fixed, paraffin-embedded tumour tissues employing two antibodies raised to short synthetic peptides from the cytoplasmic domain of the molecule. Both antibodies gave concordant staining of a series of bladder cancers known to express or lack EGF receptors. There was no cross-reaction with the related c-erbB-2 protein, which was also over-expressed in some cases. Cancers with EGF receptor expression also expressed high levels of TGF-alpha, a receptor agonist.     

Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma.

Male breast carcinomas are probably hormone-dependent, but receptor studies are few because this is a relatively rare tumour. We have studied 21 cases of male breast carcinoma immunohistochemically for oestrogen receptor (ER) and epidermal growth factor receptor (EGFR) expression employing the antibodies ER-ICA and 12E on formalin-fixed, paraffin-embedded material. In our series, 86 per cent of male breast cancers were ER-positive and 76 per cent were EGFR-positive. Male breast carcinomas do not exhibit the inverse correlation between ER and EGFR expression that characterizes female breast carcinomas. Owing to the limitations of a small series, we were unable to comment on the relationship between ER and EGFR expression and patient survival. However, the relatively high incidence of ER expression may provide a growth advantage for this tumour in a male environment characterized by low levels of oestrogen. In addition, high EGFR expression may also contribute to a poor prognosis independent of ER status.     

Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression

Activating mutations in the epidermal growth factor receptor (EGFR) (7p12.3-p12.1) and in the human epidermal growth factor receptor 2 (HER2) (17q21.1) characterize a subset of lung carcinomas. These mutations may relate to the response of the tumor to the tyrosine kinase inhibitors gefitinib and erlotinib. High-resolution melting amplicon analysis is a screening technique that has been shown to be able to detect missense mutations as well as deletions and insertions in tumor DNA isolated from paraffin-embedded tissue sections. In this study, we used high-resolution melting amplicon analysis to screen for EGFR and human HER2 activating mutations in 39 patients with primary lung adenocarcinoma. There were 20 cases that showed bronchioloalveolar histology and 19 cases that did not. The EGFR exons screened were exons 18, 19, 20, and 21, and the HER2 exons screened were exons 19 and 20. Six (15%) of the 39 patients had tumors that contained EGFR activating mutations. Four of the mutations were in adenocarcinomas, which had some bronchioloalveolar features, and 2 mutations were in tumors without bronchioloalveolar features. The EGFR mutations were in exon 19 (2 cases), exon 20 (2 cases), and exon 21 (1 case). One case contained mutations in both exons 18 and 20. One (2.6%) of the 39 patients had a tumor that contained an HER2 activating mutation, and the mutation was located in exon 20. Two of the 6 EGFR mutation-positive cases showed polysomy for chromosome 7, and each one showed overexpression of EGFR as determined by immunohistochemical staining. The other EGFR mutation-positive cases did not show EGFR overexpression and appeared disomic for chromosome 7. The HER2 mutation-positive case was in an adenocarcinoma with bronchioloalveolar features. This tumor did not show overexpression of HER2 and was disomic for chromosome 17. For the non-EGFR mutation-positive cases, 4 (13%) of 32 evaluated cases showed polysomy for chromosome 7 and EGFR. No case showed EGFR gene amplification. Polysomy for chromosome 7 was not related to EGFR overexpression as estimated by immunohistochemistry. Estrogen and progesterone receptor expression was not strong in any of the cases and did not correlate with the presence of EGFR or HER2 mutations.     

人结直肠癌组织中表皮生长因子受体1与Fascin-1蛋白表达的相关性及其临床意义

目的 探讨人结直肠癌组织中表皮生长因子受体1(EGFR)与Fascin-1蛋白表达的关系及其临床意义。方法 回顾性收集2008年1月-2010年12月东阳市人民医院病理科结直肠癌石蜡标本258例和同时切除的正常结直肠组织石蜡标本72例。采用免疫组织化学EnVision法检测并比较直肠癌组织和正常结直肠组织中EGFR和Fascin-1蛋白的表达;分析结直肠癌中Fascin-1蛋白表达与结直肠癌患者临床病理特征、EGFR的关系,以及EGFR和Fascin-1蛋白的表达与患者的预后生存情况的关系。结果 (1)结直肠癌组织中Fascin-1蛋白的阳性率为38.0%(98/258),高于正常结直肠组织的阳性率0.0%(0/72),差异有统计学意义(χ²=38.901,P＜0.01)。(2)女性、结肠及低分化的结直肠癌患者中Fascin-1蛋白的阳性率高于男性、直肠及高-中分化患者(χ²=4.256、20.085、8.471,P值均＜0.05)。(3)在EGFR阳性结直肠癌患者的Fascin-1蛋白阳性表达率(42.9%,91/212)较EGFR阴性病例(15.2%,7/46)高,差异有统计学意义(χ²=12.318, P＜0.01);Spearman相关分析显示,结直肠癌组织中EGFR和Fascin-1蛋白表达呈正相关(r_s=0.219,P＜0.01)。(4)194例获得随访的结直肠癌患者5年总生存率为73.2%(142/194),5年无复发生存率为65.5%(127/194)。其中EGFR和Fascin-1均阳性患者的5年平均总生存期及5年总生存率(47.8个月、64.7%)低于非均阳性患者(54.4个月、77.8%),差异有统计学意义(χ²=5.039, P＜0.05)。结论 结直肠癌中EGFR与Fascin-1蛋白的表达呈正相关,二者同时表达与患者预后不良有关。